TY - DATA T1 - Additional file 4: of A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study PY - 2016/04/02 AU - Dae Yoo AU - Artur Racewicz AU - Jan Brzezicki AU - Roman Yatsyshyn AU - Edgardo Arteaga AU - Asta Baranauskaite AU - Carlos Abud-Mendoza AU - Sandra Navarra AU - Vladimir Kadinov AU - Irmgadt Sariego AU - Seung Hong AU - Sung Lee AU - Won Park UR - https://springernature.figshare.com/articles/journal_contribution/Additional_file_4_of_A_phase_III_randomized_study_to_evaluate_the_efficacy_and_safety_of_CT-P13_compared_with_reference_infliximab_in_patients_with_active_rheumatoid_arthritis_54-week_results_from_the_PLANETRA_study/4413491 DO - 10.6084/m9.figshare.c.3627587_D4.v1 L4 - https://ndownloader.figshare.com/files/7139894 KW - Biosimilar KW - CT-P13 KW - Infliximab KW - Rheumatoid arthritis KW - Efficacy KW - Immunogenicity KW - Safety KW - Pharmacokinetics KW - ACR20 KW - Sharp score N2 - Overview of treatment-related serious adverse events occurring by severity (n [%]). (DOC 49 kb) ER -